These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 11706971)

  • 1. Immunopathology of secondary-progressive multiple sclerosis.
    Prineas JW; Kwon EE; Cho ES; Sharer LR; Barnett MH; Oleszak EL; Hoffman B; Morgan BP
    Ann Neurol; 2001 Nov; 50(5):646-57. PubMed ID: 11706971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue remodeling in periplaque regions of multiple sclerosis spinal cord lesions.
    Lieury A; Chanal M; Androdias G; Reynolds R; Cavagna S; Giraudon P; Confavreux C; Nataf S
    Glia; 2014 Oct; 62(10):1645-58. PubMed ID: 24910450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoglobulins and complement in postmortem multiple sclerosis tissue.
    Barnett MH; Parratt JD; Cho ES; Prineas JW
    Ann Neurol; 2009 Jan; 65(1):32-46. PubMed ID: 19194879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular signature of slowly expanding lesions in progressive multiple sclerosis.
    Jäckle K; Zeis T; Schaeren-Wiemers N; Junker A; van der Meer F; Kramann N; Stadelmann C; Brück W
    Brain; 2020 Jul; 143(7):2073-2088. PubMed ID: 32577755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demyelination versus remyelination in progressive multiple sclerosis.
    Bramow S; Frischer JM; Lassmann H; Koch-Henriksen N; Lucchinetti CF; Sørensen PS; Laursen H
    Brain; 2010 Oct; 133(10):2983-98. PubMed ID: 20855416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination.
    Storch MK; Piddlesden S; Haltia M; Iivanainen M; Morgan P; Lassmann H
    Ann Neurol; 1998 Apr; 43(4):465-71. PubMed ID: 9546327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cuprizone model: regional heterogeneity of pathology.
    Wergeland S; Torkildsen Ø; Myhr KM; Mørk SJ; Bø L
    APMIS; 2012 Aug; 120(8):648-57. PubMed ID: 22779688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement C3 on microglial clusters in multiple sclerosis occur in chronic but not acute disease: Implication for disease pathogenesis.
    Michailidou I; Naessens DM; Hametner S; Guldenaar W; Kooi EJ; Geurts JJ; Baas F; Lassmann H; Ramaglia V
    Glia; 2017 Feb; 65(2):264-277. PubMed ID: 27778395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parenchymal accumulation of CD163+ macrophages/microglia in multiple sclerosis brains.
    Zhang Z; Zhang ZY; Schittenhelm J; Wu Y; Meyermann R; Schluesener HJ
    J Neuroimmunol; 2011 Aug; 237(1-2):73-9. PubMed ID: 21737148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions.
    Brink BP; Veerhuis R; Breij EC; van der Valk P; Dijkstra CD; Bö L
    J Neuropathol Exp Neurol; 2005 Feb; 64(2):147-55. PubMed ID: 15751229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microglia are activated to become competent antigen presenting and effector cells in the inflammatory environment of the Theiler's virus model of multiple sclerosis.
    Mack CL; Vanderlugt-Castaneda CL; Neville KL; Miller SD
    J Neuroimmunol; 2003 Nov; 144(1-2):68-79. PubMed ID: 14597100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple sclerosis: distribution of inflammatory cells in newly forming lesions.
    Henderson AP; Barnett MH; Parratt JD; Prineas JW
    Ann Neurol; 2009 Dec; 66(6):739-53. PubMed ID: 20035511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica.
    Lucchinetti CF; Mandler RN; McGavern D; Bruck W; Gleich G; Ransohoff RM; Trebst C; Weinshenker B; Wingerchuk D; Parisi JE; Lassmann H
    Brain; 2002 Jul; 125(Pt 7):1450-61. PubMed ID: 12076996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early cellular events in multiple sclerosis. Intimations of an extrinsic myelinolytic antigen.
    Gay FW
    Clin Neurol Neurosurg; 2006 Mar; 108(3):234-40. PubMed ID: 16364541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of ADAM-17 expression in active lesions in multiple sclerosis.
    Plumb J; McQuaid S; Cross AK; Surr J; Haddock G; Bunning RA; Woodroofe MN
    Mult Scler; 2006 Aug; 12(4):375-85. PubMed ID: 16900751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement activated C4d immunoreactive oligodendrocytes delineate small cortical plaques in multiple sclerosis.
    Schwab C; McGeer PL
    Exp Neurol; 2002 Mar; 174(1):81-8. PubMed ID: 11869036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of early components of complement targets myelin and oligodendrocytes in the aged rhesus monkey brain.
    Duce JA; Hollander W; Jaffe R; Abraham CR
    Neurobiol Aging; 2006 Apr; 27(4):633-44. PubMed ID: 15992964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relative number of macrophages/microglia expressing macrophage colony-stimulating factor and its receptor decreases in multiple sclerosis lesions.
    Werner K; Bitsch A; Bunkowski S; Hemmerlein B; Brück W
    Glia; 2002 Oct; 40(1):121-9. PubMed ID: 12237849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple sclerosis. Oligodendrocyte proliferation and differentiation in fresh lesions.
    Prineas JW; Kwon EE; Goldenberg PZ; Ilyas AA; Quarles RH; Benjamins JA; Sprinkle TJ
    Lab Invest; 1989 Nov; 61(5):489-503. PubMed ID: 2811298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pathology of primary progressive multiple sclerosis.
    Brück W; Lucchinetti C; Lassmann H
    Mult Scler; 2002 Apr; 8(2):93-7. PubMed ID: 11990878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.